Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orantinib

Next Previous
X
Search
Drug Profile

Orantinib

Alternative Names: SU 006668; SU 6668; TSU-68

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Antineoplastics; Indoles; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 31 Jul 2014 Taiho Pharmaceutical terminates the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 18 Feb 2014 Taiho Pharmaceutical completes enrolment in the phase III ORIENTAL trial for liver cancer (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 13 Apr 2012 Orantinib is still in phase I trials for Non-small cell lung cancer in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top